SPRO vs ABBV

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -53. 8% for Spero Therapeutics, Inc. (SPRO). AbbVie Inc. (ABBV) offers the better valuation at 86. 5x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Spero Therapeutics, Inc. (SPRO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Spero Therapeutics, Inc.

is actually cheaper at 3. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +102. 8%, compared to -80. 2% for Spero Therapeutics, Inc. (SPRO). Over 10 years, the gap is even starker: ABBV returned +306. 7% versus SPRO's -78. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Spero Therapeutics, Inc. 's 0. 90β — meaning SPRO is approximately 167% more volatile than ABBV relative to the S&P 500.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus -53. 8% for Spero Therapeutics, Inc. (SPRO). On earnings-per-share growth, the picture is similar: AbbVie Inc. grew EPS -0. 8% year-over-year, compared to -395. 3% for Spero Therapeutics, Inc.. Over a 3-year CAGR, SPRO leads at 150. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -142. 9% for Spero Therapeutics, Inc. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -152. 9% for SPRO. At the gross margin level — before operating expenses — ABBV leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Spero Therapeutics, Inc.

(SPRO) trades at 3. 8x forward P/E versus 14. 4x for AbbVie Inc. — 10. 7x cheaper on a one-year earnings basis.

In this comparison, ABBV (3.

2% yield) pays a dividend. SPRO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +306. 7% 10Y return). Both have compounded well over 10 years (ABBV: +306. 7%, SPRO: -78. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SPRO is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while SPRO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.